Vaccinia virus protein C4 inhibits NF-κB activation and promotes virus virulence

Journal of General Virology

Volumn 93, Issue PART 10, 2012, Pages 2098-2108

  Ember, Stuart W J ^a,b   Ren, Hongwei ^a,b   Ferguson, Brian J ^a,b   Smith, Geoffrey L ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; VACCINIA VIRUS PROTEIN C4; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL LYSATE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VACCINIA; VACCINIA VIRUS; VIROGENESIS; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; COMPUTATIONAL BIOLOGY; CYTOPLASM; FEMALE; HEK293 CELLS; HELA CELLS; HUMANS; INTERLEUKIN-1BETA; KINETICS; LUNG; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NF-KAPPA B; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; PROMOTER REGIONS, GENETIC; VACCINIA; VACCINIA VIRUS; VIRAL LOAD; VIRAL PROTEINS; VIRULENCE; VIRUS REPLICATION;

ANIMALIA; MURINAE; MUS; ORTHOPOXVIRUS; VACCINIA VIRUS;

EID: 84866327131     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.045070-0     Document Type: Article

References (54)

1. Alcami, A. (2003). Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3, 36-50.
2. Alcamí, A. & Smith, G. L. (1992). A soluble receptor for interleukin-1b encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153-167.
3. Alcamí, A. & Smith, G. L. (1996). A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci U S A 93, 11029-11034.
4. Assarsson, E., Greenbaum, J. A., Sundström, M., Schaffer, L., Hammond, J. A., Pasquetto, V., Oseroff, C., Hendrickson, R. C., Lefkowitz, E. J. & other authors (2008). Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105, 2140-2145.
5. Bartlett, N., Symons, J. A., Tscharke, D. C. & Smith, G. L. (2002). The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 83, 1965-1976.
6. Benfield, C. T., Mansur, D. S., McCoy, L. E., Ferguson, B. J., Bahar, M. W., Oldring, A. P., Grimes, J. M., Stuart, D. I., Graham, S. C. & Smith, G. L. (2011). Mapping the IkB kinase b (IKKb)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKb-mediated activation of nuclear factor kB. J Biol Chem 286, 20727-20735.
7. Bennink, J. R., Yewdell, J. W., Smith, G. L., Moller, C. & Moss, B. (1984). Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311, 578-579.
8. Bennink, J. R., Yewdell, J. W., Smith, G. L. & Moss, B. (1986). Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol 57, 786-791.
9. Bowie, A., Kiss-Toth, E., Symons, J. A., Smith, G. L., Dower, S. K. & O'Neill, L. A. (2000). A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 97, 10162-10167.
10. Chen, R. A., Jacobs, N. & Smith, G. L. (2006). Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol 87, 1451-1458.
11. Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. (2008). Inhibition of IkB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4, e22.
12. Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006). Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87, 29-38.
13. Cooray, S., Bahar, M. W., Abrescia, N. G., McVey, C. E., Bartlett, N. W., Chen, R. A., Stuart, D. I., Grimes, J. M. & Smith, G. L. (2007). Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88, 1656-1666.
14. Cudmore, S., Cossart, P., Griffiths, G. & Way, M. (1995). Actin-based motility of vaccinia virus. Nature 378, 636-638.
15. DiPerna, G., Stack, J., Bowie, A. G., Boyd, A., Kotwal, G., Zhang, Z., Arvikar, S., Latz, E., Fitzgerald, K. A. & Marshall, W. L. (2004). Poxvirus protein N1L targets the I-kB kinase complex, inhibits signaling to NF-kB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kB and IRF3 signaling by Toll-like receptors. J Biol Chem 279, 36570-36578.
16. Doceul, V., Hollinshead, M., van der Linden, L. & Smith, G. L. (2010). Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327, 873-876.
17. Fahy, A. S., Clark, R. H., Glyde, E. F. & Smith, G. L. (2008). Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol 89, 2377-2387.
18. Falkner, F. G. & Moss, B. (1990). Transient dominant selection of recombinant vaccinia viruses. J Virol 64, 3108-3111.
19. Fenner, F., Anderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and its Eradication. Geneva: World Health Organization.
20. Gedey, R., Jin, X. L., Hinthong, O. & Shisler, J. L. (2006). Poxviral regulation of the host NF-kB response: the vaccinia virus M2L protein inhibits induction of NF-kB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol 80, 8676-8685.
21. Gloeckner, C. J., Boldt, K., Schumacher, A., Roepman, R. & Ueffing, M. (2007). A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7, 4228-4234.
22. Goebel, S. J., Johnson, G. P., Perkus, M. E., Davis, S. W., Winslow, J. P. & Paoletti, E. (1990). The complete DNA sequence of vaccinia virus. Virology 179, 247-266, 517-563.
23. Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A., Whalen, D. M., Abrescia, N. G., Alderton, D., Owens, R. J., Stuart, D. I. & other authors (2008). Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kB rather than apoptosis. PLoS Pathog 4, e1000128.
24. Gubser, C., Hué, S., Kellam, P. & Smith, G. L. (2004). Poxvirus genomes: a phylogenetic analysis. J Gen Virol 85, 105-117.
25. Harte, M. T., Haga, I. R., Maloney, G., Gray, P., Reading, P. C., Bartlett, N. W., Smith, G. L., Bowie, A. & O'Neill, L. A. (2003). The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197, 343-351.
26. Hayden, M. S. & Ghosh, S. (2008). Shared principles in NF-kB signaling. Cell 132, 344-362.
27. Jacobs, N., Chen, R. A., Gubser, C., Najarro, P. & Smith, G. L. (2006). Intradermal immune response after infection with Vaccinia virus. J Gen Virol 87, 1157-1161.
28. Kluczyk, A., Siemion, I. Z., Szewczuk, Z. & Wieczorek, Z. (2002). The immunosuppressive activity of peptide fragments of vaccinia virus C10L protein and a hypothesis on the role of this protein in the viral invasion. Peptides 23, 823-834.
29. Maluquer de Motes, C., Cooray, S., Ren, H., Almeida, G. M., McGourty, K., Bahar, M. W., Stuart, D. I., Grimes, J. M., Graham, S. C. & Smith, G. L. (2011). Inhibition of apoptosis and NF-kB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog 7, e1002430.
30. McCoy, L. E., Fahy, A. S., Chen, R. A. & Smith, G. L. (2010). Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kB activation. J Gen Virol 91, 2216-2220.
31. McMichael, A. J., Michie, C. A., Gotch, F. M., Smith, G. L. & Moss, B. (1986). Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 67, 719-726.
32. Moss, B. (1996). Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 93, 11341-11348.
33. Moss, B. (2007). Poxviridae: the viruses and their replicaton. In Fields Virology, 5th edn, pp. 2905-2946. Edited by D. M. Knipe. Philadelphia, PA: Lippincott Williams & Wilkins.
34. Moss, B., Smith, G. L., Gerin, J. L. & Purcell, R. H. (1984). Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311, 67-69.
35. Myskiw, C., Arsenio, J., van Bruggen, R., Deschambault, Y. & Cao, J. (2009). Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kB, and IRF3 pathways. J Virol 83, 6757-6768.
36. Niles, E. G. & Seto, J. (1988). Vaccinia virus gene D8 encodes a virion transmembrane protein. J Virol 62, 3772-3778.
37. Paoletti, E., Lipinskas, B. R., Samsonoff, C., Mercer, S. & Panicali, D. (1984). Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A 81, 193-197.
38. Parkinson, J. E. & Smith, G. L. (1994). Vaccinia virus gene A36R encodes a Mr 43-50 K protein on the surface of extracellular enveloped virus. Virology 204, 376-390.
39. Reading, P. C. & Smith, G. L. (2003). A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J Gen Virol 84, 1973-1983.
40. Schröder, M., Baran, M. & Bowie, A. G. (2008). Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKe-mediated IRF activation. EMBO J 27, 2147-2157.
41. Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A. & McFadden, G. (2003). Poxviruses and immune evasion. Annu Rev Immunol 21, 377-423.
42. Shisler, J. L. & Jin, X. L. (2004). The vaccinia virus K1L gene product inhibits host NF-kB activation by preventing IkBa degradation. J Virol 78, 3553-3560.
43. Smith, G. L. (1994). Virus strategies for evasion of the host response to infection. Trends Microbiol 2, 81-88.
44. Smith, G. L. & Chan, Y. S. (1991). Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J Gen Virol 72, 511-518.
45. Smith, G. L., Mackett, M. & Moss, B. (1983). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302, 490-495.
46. Stack, J., Haga, I. R., Schröder, M., Bartlett, N. W., Maloney, G., Reading, P. C., Fitzgerald, K. A., Smith, G. L. & Bowie, A. G. (2005). Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201, 1007-1018.
47. Tscharke, D. C. & Smith, G. L. (1999). A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80, 2751-2755.
48. Tscharke, D. C., Reading, P. C. & Smith, G. L. (2002). Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 83, 1977-1986.
49. Unterholzner, L., Sumner, R. P., Baran, M., Ren, H., Mansur, D. S., Bourke, N. M., Randow, F., Smith, G. L. & Bowie, A. G. (2011). Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 7, e1002247.
50. Upton, C., Slack, S., Hunter, A. L., Ehlers, A. & Roper, R. L. (2003). Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J Virol 77, 7590-7600.
51. Valentine, R. & Smith, G. L. (2010). Inhibition of the RNA polymerase III-mediated dsDNA-sensing pathway of innate immunity by vaccinia virus protein E3. J Gen Virol 91, 2221-2229.
52. Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. (1990). Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71, 2761-2767.
53. Yewdell, J. W., Bennink, J. R., Smith, G. L. & Moss, B. (1985). Influenza A virus nucleoprotein is a major target antigen for crossreactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82, 1785-1789.
54. Yuwen, H., Cox, J. H., Yewdell, J. W., Bennink, J. R. & Moss, B. (1993). Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. Virology 195, 732-744.